A hepatokine is a collective term for liver-derived secretory factors whose previously-unrecognized functions have been recently elucidated. We have rediscovered
selenoprotein P (SeP) and leukocyte cell-derived
chemotaxin 2 (LECT2) as hepatokines that are involved in the development of
insulin resistance and
hyperglycemia. The aim of this study was to determine whether and, if so, how oral
glucose loading alters the two hepatokines in humans. We measured concentrations of serum SeP and plasma LECT2 during 75 g oral
glucose tolerance test (OGTT) (n = 20) in people with various degrees of
glucose tolerance. In OGTT, concentrations of both serum SeP and plasma LECT2 decreased at 120 min compared with the baseline values, irrespective of the severity of
glucose intolerance. Decrement of serum SeP during OGTT showed no correlations to the clinical parameters associated with
insulin resistance or insulin secretion. In multiple stepwise regression analyses, plasma
cortisol was selected as the variable to explain the changes in plasma concentrations of LECT2. The current data reveal the acute inhibitory actions of oral intake of
glucose on circulating SeP and LECT2 in humans, irrespective of the severity of
glucose intolerance. This study suggests that circulating SeP is regulated by the unknown clinical factors other than
insulin and
glucose during OGTT.